Tag: anticoagulation
Mechanical thrombectomy demonstrates superior outcomes to anticoagulation in DVT patients, analysis...
Mechanical thrombectomy using the ClotTriever device (Inari Medical) for iliofemoral deep vein thrombosis (DVT) was found to be “associated with significantly” lower Villalta scores...
Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients
Treatment of critically ill COVID-19 patients with full-dose anticoagulation lowers the risk of venous and arterial clotting complications by 44% compared with the standard...
Anticoagulants effective for pulmonary embolism resolution in hospitalised COVID-19 patients
Anticoagulants alone are associated with a high rate of resolution of pulmonary embolism (PE) in patients with acute PE and COVID-19 infection. This was...
SVT patients bear “significant risk” of thromboembolic complications at three months,...
Despite a high rate of initial anticoagulation, patients with isolated superficial vein thrombosis (SVT) are at risk of thromboembolic complications—including recurrent or extended SVT...
What an interventionalist needs to know about DOACs in 2021
The publication of positive new data and a need to minimise hospital visits during the COVID-19 pandemic has seen a general trend towards using...
Thrombosis is major by-product of infection with COVID-19, but evidence to...
Manj Gohel (Cambridge, UK), one of the editors-in-chief of Venous News, introduces a special COVID-19 video with leading thrombosis and haemostasis experts, including Beverley...
No difference in PE incidence between patients treated with IVC filters...
In a case-control study of patients with perceived contraindications to anticoagulation, who either received or did not receive inferior vena cava (IVC) filters, no...
FDA approves first generics of Eliquis for prophylaxis of DVT and...
The US Food and Drug Administration (FDA) has announced the approval of two applications for the first generics of Eliquis (apixaban) tablets, to reduce...
RE-SPECT trial establishes efficacy of Pradaxa for treatment of CVT patients
Boehringer Ingelheim has announced the publication of primary analysis from RE-SPECT CVT, the first exploratory, prospective, randomised controlled study of a NOAC in patients...
Decision-making in the choice of anticoagulants following deep venous stenting
Deep venous stenting has become increasingly used to treat patients with pathological obstruction of venous return in the femoro-iliocaval venous segment following the development of new...
ATTRACT results are “a springboard” for future pharmacomechanical thrombolysis research
Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of...